VIR
Vir Biotechnology, Inc.
VIR
Vir Biotechnology, Inc.
Vir Biotechnology, Inc. (VIR) Q2 2026 Earnings Call Transcript
Vir Biotechnology is entering a catalyst-rich period with key clinical trial readouts from the ECLIPSE program in hepatitis delta plus updates from its T-cell engagers in oncology indications. VIR has